Abstract: A battery assembly according to an exemplary aspect of the present disclosure includes, among other things, a plurality of battery cells and a support structure positioned about the plurality of battery cells. The support structure includes at least one sidewall and the at least one sidewall includes a first flange that extends adjacent a top surface of each of the plurality of battery cells and a second flange that extends beyond a bottom surface of each of the plurality of battery cells.

Abstract: A vehicle including a pair of spaced apart battery cell arrays, a pair of sub-structures configured to retain the arrays, and a thermal plate assembly disposed between the arrays is provided. Each of the sub-structures may include opposing endplates and opposing upper and lower sidewalls secured to the endplates and each having a flange extending toward and overlapping with the respective flange of the other sub-structure to join the sub-structures without mechanical fastening. The thermal plate assembly may be disposed between the overlapping flanges and the arrays to form a sandwich formation. The thermal plate assembly may include at least one thermal interface component disposed on a side of a thermal plate, and in contact with a portion of at least one of the battery cell arrays.

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

Abstract: A traction battery assembly for a vehicle includes an array of cells stacked on a tray. The array of cells defines opposing longitudinal sides and opposing lateral sides. First and second L-shaped components are attached to the tray. Each of the components includes an end wall and a sidewall that are integrally formed to define a substantially 90° corner. The first and second components are attached together such that each of the sidewalls is disposed adjacent one of the longitudinal sides and each of the end walls is disposed adjacent one of the lateral sides to form a housing around the tray that has an open top and an open bottom.

Abstract: An exemplary battery assembly includes a first terminal holder, and a terminal at least partially surrounded by the first terminal holder. The first terminal holder includes a locating feature to position the first terminal holder relative to a second terminal holder.

Abstract: Sonic Hedgehog modulators and methods of use thereof are provided for.

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

Abstract: Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer.

Abstract: The present invention relates to the use of rosamine derivative compounds, as described herein, in detecting differentiated forms of a cell type of interest in a sample and in screening for compounds which inhibit differentiation of the cell type of interest.

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

Abstract: Sonic Hedgehog modulators and methods of use thereof are provided for.

Abstract: Compounds including various oligomers of piperlongumine and/or piperlongumine analogues as well as certain piperlongumine analogues that exhibit improved toxicity to cancer cells are disclosed. Also provided are compositions that comprise the compounds, methods of making compositions comprising the compounds, methods of making the compounds, and the use of compounds in methods for treating cancer.

Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

Abstract: The present invention relates to the use of rosamine derivative compounds, as described herein, in detecting differentiated forms of a cell type of interest in a sample and in screening for compounds which inhibit differentiation of the cell type of interest.

Abstract: The present invention provides novel dihydropyrancarboxamide compounds of formula (I): and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R1-R6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

Abstract: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell proliferation and differentiation in vitro and in vivo.

Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.

Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands.

Abstract: Compounds related to lactacystin and lactacystin ?-lactone, pharmaceutical compositions containing the compounds, and methods of use.

Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.